BrightHeart, a Paris-based developer of AI software for prenatal ultrasound, said it has closed an €11 million Series A financing to fund U.S. commercialization, broader European expansion and continued product development for its B-Right AI Platform.
The round was co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and founding investor Sofinnova Partners, as well as clinician and angel backers including Professor Laurent Salomon and medtech entrepreneurs Sacha Loiseau and John Gridley.
BrightHeart said its platform is designed to deliver “expert-level” ultrasound screening for complex fetal organs, helping OB-GYNs improve detection of congenital defects—particularly congenital heart defects—while integrating into routine workflows to support exam completeness, speed and diagnostic confidence.
The company said the financing follows momentum in 2025 that included five FDA clearances, partnerships with academic centers and two peer-reviewed publications in Obstetrics & Gynecology. BrightHeart also highlighted clinical validation that it said improved CHD detection to more than 96%, while reducing errors and improving efficiency.
KEY QUOTES:
“This new round of funding empowers us to accelerate BrightHeart’s mission of making AI the new standard of care in prenatal ultrasound.” “Our goal is to enhance diagnostic accuracy, improve outcomes for families and babies, and streamline clinical workflows for healthcare professionals.” “We are thrilled to have the support of our investors, who bring not only deep expertise in healthcare innovation but also proven experience in scaling companies globally.”
Cécile Dupont, CEO, BrightHeart and Partner, Sofinnova Partners
“BrightHeart has built a defensible clinical foundation in one of the most complex areas of prenatal imaging.”
Julien Andrieux, Partner, Odyssée Venture
“By pairing expert-level screening with tangible workflow benefits and seamless integration, the company is well positioned to become a reference platform in prenatal ultrasound.”
Leïla Nicolas, Partner, GO Capital
“At the Mussallem CHD Alliance, we envision a future where babies born with congenital heart defects have access to early and accurate diagnosis, and BrightHeart’s platform gives us confidence that this future is within reach.” “By embedding advanced AI directly into ultrasound workflows, BrightHeart is paving the way for expert-level fetal heart screening to become part of routine prenatal care.”
Orin Herskowitz, President, Mussallem CHD Alliance
